Form 4: Fulgent Genetics CSO Sells Shares for Tax Obligations

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, disposed of 1,331 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a disposition of common stock.
• The transaction occurred on January 26, 2026, and was made pursuant to a Rule 10b5-1(c) plan.
• A total of 1,331 shares were withheld from the reporting person to satisfy tax withholding obligations.
• These obligations arose upon the vesting of certain restricted stock units (RSUs).
• The RSUs were assumed pursuant to an Agreement and Plan of Merger dated November 7, 2022.
• The shares were disposed of at a price of $27.53 per share.
• Following this transaction, Hanlin Gao beneficially owns 951,559 shares of Fulgent Genetics common stock.

Sentiment

Score: 5

Explanation: This is a routine insider transaction for tax purposes, neither inherently positive nor negative for the company's operational performance or strategic direction.

Positives

• The vesting of restricted stock units indicates that the company's employee retention and compensation structure for executives is functioning as intended.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and routine event rather than a discretionary sale based on new information.

Negatives

• A minor reduction in the direct beneficial ownership by a key officer, although for tax purposes, slightly decreases insider holdings.

Industry Context

This is a routine insider transaction, common across all industries for executive compensation, particularly for managing tax liabilities associated with restricted stock unit vesting. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction represents a minor, routine adjustment in insider ownership and does not typically impact the company's fundamental value or operational performance.
• Employees: The vesting of RSUs and subsequent tax-related disposition demonstrates the functioning of the company's executive compensation program.

Key Dates

Recommendation

The reported transaction is a routine disposition of shares by a Chief Scientific Officer to cover tax withholding obligations upon the vesting of restricted stock units. This is a common practice for executive compensation and does not reflect a change in the company's operational performance, strategic direction, or the insider's long-term confidence. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Fulgent Genetics, FLGT, Insider Transaction, Form 4, Stock Sale, Chief Scientific Officer, Hanlin Gao, Restricted Stock Units, Tax Withholding, 10b5-1 Plan